Sergio Occhipinti, PhD, is a medtech founder and scientist dedicated to advancing urine-based diagnostics for prostate cancer. As CEO of NIB Biotec since 2017, he has driven the company’s scale-up, closing two investment rounds and obtaining competitive public grants, enabling faster R&D, validation, and market access for innovative in vitro diagnostics. Sergio earned his PhD in Molecular Medicine at the University of Turin and brings 15+ years of preclinical and clinical research experience. His work has focused on urinary liquid biopsy, immuno-oncology, and the design of novel clinical protocols. He is an inventor on patents related to prostate cancer biomarkers and diagnostics, underscoring his commitment to rigorous, translational science. To bridge lab and market, he completed ...